Back to Results
Elias Reichel, MD
Accepting New Patients
Meet Elias Reichel, MD
Title(s)
Vice Chair for Research and Education, Department of Ophthalmology; Director, Vitreoretinal Diseases and Surgery Service; Co-Director, Electrophysiology Service; Director, Medical Retina Fellowship; Professor and Vice Chair, Department of Ophthalmology, Tufts University School of Medicine
Department + Services
Ophthalmology
Clinical Focus Areas
Vitreoretinal diseases and surgery, diabetic eye disease, macular degeneration,
hereditary retinal degenerations, retinal venous occlusive disease
Research Focus Areas
Dr. Reichel has a special research interest in macular degeneration, hereditary retinal degenerations, and diabetic retinopathy. He is the principal investigator for several clinical trials evaluating experimental treatments for retinal disorders. Dr. Reichel has developed lenses for visualizing laser treatments, vitrectomy lens systems and a topical anesthetic for ocular procedures.
Seeing Patients In
Boston, 617-636-4600
Request Appointment
Programs + Specialties |
|
Training + Education |
Albert Einstein College of Medicine; Massachusetts Eye and Ear Infirmary; New England Eye Center; Children's Hospital, Boston
|
Board Certifications |
Ophthalmology |
NPI # |
1053376939 |
Gender |
Male |
Language(s) |
Spanish |
Accepted Insurances |
View Accepted Insurances at Tufts MC + Tufts Children's Hospital
|
New England Eye Center - Boston
800 Washington St., #450
Boston, MA 02111
Phone #: 617-636-4600
Fax #: 617-636-4866
|
2009 Senior Honor Award, American Academy of Ophthalmology
2009 Best Doctors in America
Dryja TP, McGee TL, Reichel E, Hahn LB, Crowley GS, Yandell DW, Sandberg MA, Berson EL. A Point Mutation of the Rhodopsin Gene in One Form of Retinitis Pigmentosa. Nature. 1990; 343:364-366.
Reichel E, Berrocal AM, Ip M, Kroll AJ, Desai V, Duker JS, Puliafito CA. Transpupillary Thermotherapy (TTT) of Occult Subfoveal Choroidal Neovascularization in Patients with Age-Related Macular Degeneration. Ophthalmology. 1999;106:1908-1914.
Greenberg PB, Martidis A, Rogers AH, Duker JS, Reichel E. Intravitreal triamcinolone acetonide for macular edema due to central retinal vein occlusion. Br J Ophthalmol. 2002; 86(2):247-8.
Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, Baumal C. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109(5):920-7.
Mainster MA, Reichel E, Harrington PG. A wide-field, high-resolution ophthalmoscopic contact lens. Ophthalmic Surg Lasers Imaging. 2003;34:76-7.
Busbee BG, Alam A, Reichel E. Lidocaine Hydrochloride Gel for Ocular Anesthesia Results of a Prospective, Randomized Study. Ophthalmic Surg Lasers Imaging 2008;39:386-390.
Goldberg RA, Reichel E, Oshry LJ. Bilateral toxoplasmosis retinitis associated with ruxolitnib. New Engl J Med. 2013 Aug 15;369-3.
1985 Alpha Omega Alpha
1987 Association for Research in Vision and Ophthalmology
1991 FOVEA Fluorescein Angiography Club
1992 Massachusetts Eye and Ear Infirmary, Alumni Association
1993 American Academy of Ophthalmology
1994 Massachusetts Medical Society
1994 Massachusetts Society of Eye Physicians and Surgeons
1995 American Society of Retina Specialists
1995 Macula Society
2001 Retina Society
2013 AAO Research, Regulatory, and External Scientific Affairs Committee
In addition to Dr. Reichel’s active clinical and research work at New England Eye Center, he has several entrepreneurial endeavors:
Developer of Transpupillary Thermotherapy for Choroidal Neovascularizaton.
Developer of 3.5% lidocaine gel for ocular anesthesia – FDA approved 2008.
Founder of Hemera Biosciences – developing a gene therapy for dry age-related macular degeneration entering phase 1 March, 2017.
Dr. Reichel also serves on the Editorial Board of Retina Today,and is an Editor of Clinical Therapeutics.